These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8433280)

  • 1. HIV protease inhibitors: their anti-HIV activity and potential role in treatment.
    Robins T; Plattner J
    J Acquir Immune Defic Syndr (1988); 1993 Feb; 6(2):162-70. PubMed ID: 8433280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of HIV-1 protease.
    Meek TD
    J Enzyme Inhib; 1992; 6(1):65-98. PubMed ID: 1285304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HIV-1 protease as a therapeutic target for AIDS.
    Debouck C
    AIDS Res Hum Retroviruses; 1992 Feb; 8(2):153-64. PubMed ID: 1540403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases.
    Tang J; Hartsuck JA
    FEBS Lett; 1995 Jun; 367(2):112-6. PubMed ID: 7796905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy.
    Deeks SG
    Adv Exp Med Biol; 1999; 458():175-82. PubMed ID: 10549390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a novel screen for protease inhibitors.
    Gillim L; Gusella GL; Vargas J; Marras D; Klotman ME; Cara A
    Clin Diagn Lab Immunol; 2001 Mar; 8(2):437-40. PubMed ID: 11238235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of protease inhibitors on HIV-1 maturation and infectivity.
    Jardine DK; Tyssen DP; Birch CJ
    Antiviral Res; 2000 Jan; 45(1):59-68. PubMed ID: 10774590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HIV protease and therapies for AIDS.
    Korant BD; Rizzo CJ
    Adv Exp Med Biol; 1997; 421():279-84. PubMed ID: 9330709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural mechanisms of HIV drug resistance.
    Erickson JW; Burt SK
    Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
    Tomasselli AG; Heinrikson RL
    Biochim Biophys Acta; 2000 Mar; 1477(1-2):189-214. PubMed ID: 10708858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapeutic possibilities for human immunodeficiency virus/acquired immunodeficiency syndrome.
    Balint GA
    Pharmacol Ther; 2001 Jan; 89(1):17-27. PubMed ID: 11316511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.
    Ghosh AK; Osswald HL; Prato G
    J Med Chem; 2016 Jun; 59(11):5172-208. PubMed ID: 26799988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 protease inhibitors.
    McDonald CK; Kuritzkes DR
    Arch Intern Med; 1997 May; 157(9):951-9. PubMed ID: 9140265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteolytic events of HIV-1 replication as targets for therapeutic intervention.
    Tözsér J; Oroszlan S
    Curr Pharm Des; 2003; 9(22):1803-15. PubMed ID: 12871198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.
    O'Meara D; Wilbe K; Leitner T; Hejdeman B; Albert J; Lundeberg J
    J Clin Microbiol; 2001 Feb; 39(2):464-73. PubMed ID: 11158091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV protease inhibitors: peptidomimetic drugs and future perspectives.
    Abdel-Rahman HM; Al-karamany GS; El-Koussi NA; Youssef AF; Kiso Y
    Curr Med Chem; 2002 Nov; 9(21):1905-22. PubMed ID: 12369875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness.
    Berkhout B
    J Biomed Sci; 1999; 6(5):298-305. PubMed ID: 10494036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
    Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
    J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
    Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
    Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.